



Market Announcement

11 March 2019

Antisense Therapeutics Limited (ASX: ANP) – Trading Halt

Description

The securities of Antisense Therapeutics Limited ('ANP') will be placed in trading halt at the request of ANP, pending it releasing an announcement. Unless ASX decides otherwise, the securities will remain in trading halt until the earlier of the commencement of normal trading on Wednesday, 13 March 2019 or when the announcement is released to the market.

Issued by

Kate Kidson

Principal Adviser, Listings Compliance (Melbourne)

Monday 11 March 2019

Kate Kidson
Principal Adviser
Listings Compliance (Melbourne)
ASX Compliance Pty Limited

Email: Kate.kidson@asx.com.au

Dear Kate,

Request for Trading Halt for Antisense Therapeutics Limited

In accordance with ASX Listing Rule 17.1, the Directors of Antisense Therapeutics Limited (“the Company”) request an immediate trading halt in respect of its securities (ASX Code: ANP).

In requesting the trading halt, the Company provides the following information:

- The trading halt is requested in respect of a placement to accelerate the development planned for ATL1102 in DMD;
- Unless otherwise requested by the Company, the Company requests the trading halt to remain in place until the earlier of the release of an announcement to the market or the morning of Wednesday 13 March 2019; and
- The Company is not aware of any reason why the trading halt should not be granted or of any other information necessary to inform the market about the trading halt.

Yours sincerely,



Phillip Hains
Company Secretary